Medicenna Brief: Increased Cash Balance to US$37 Million Following a $20 Million Investment by RA Capital Extending Runway Into Mid-2026

MT NewswiresJun 27 08:24 ET

Medicenna Brief: Net Loss for the Year Ended March 31, 2024, Was US$25.5 Million or $0.37 per Share

MT NewswiresJun 27 08:23 ET

Medicenna Secures European Approval for Phase 1/2 ABILITY-1 Study to Europe

MT NewswiresJun 26 08:45 ET

Medicenna Brief: Reporting "Significant" Survival Benefit in Patients With Recurrent Glioblastoma Following Treatment With Bizaxofusp When Compared to a "Matched External Control Arm"

MT NewswiresJun 3 08:03 ET

Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response With MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum

Stockhouse May 31 09:29 ET

Canadian Investment Regulatory Organization Trading Halt - MDNA

Stockhouse Apr 26 08:07 ET